CTRI/2018/09/015846招募中3 期
A Phase III Randomized DoubleBlind Placebo Controlled Study of Curcumin to Reduce Mucositis in Autologous Transplant Setting
The Terry Fox Research Institute0 个研究点目标入组 0 人开始时间: 待定最近更新:
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •Male or female patients 18 years and above Patients who give written informed consent
- •Patients with performance status â?? 0,1 or 2 (ECOG scale)
- •Patients requiring autologous transplant for any malignant disease with any of the following high dose chemotherapy regimens
- •Melphalan- 200 mg/m2 or more (MEL-200 mg/m2)
- •Busulfan and Melphalan (BuMEL)
- •Carmustine (BCNU), Etoposide, Cytosine Arabinoside and Melphalan ( BEAM)
- •Patients who have creatinine clearance > 50 ml/min
- •Patients with serum bilirubin levels < 2mg/dl. and serum liver enzymes (ALT or AST or both) lesser than 5 times the upper limit of normal value
排除标准
- •Patients who are on NSAIDs, aspirin, antioxidants or systemic steroids for more than 3 months and the last dose taken within the last one week.
- •Patients being treated for active infection at the time of starting high dose chemotherapy.
研究者
相似试验
进行中（未招募）
1 期
Safety and efficacy study of roxadustat to treat anemia in patients with lower risk Myelodysplastic Syndrome (MDS), who require 1 to 4 packs of Red Blood Cells through transfusion every 8-weeks.Anemia due to Myelodysplastic Syndrome (MDS) in International Prognostic Scoring System – Revised Very Low, Low, or Intermediate Risk with <5% Blasts, and has low red blood cell transfusion burden (requires 1 to 4 packed red blood cell units per 8-week period)EUCTR2017-001773-17-BEFibroGen, Inc.303
进行中（未招募）
1 期
Safety and efficacy study of roxadustat to treat anemia in patients with lower risk Myelodysplastic Syndrome (MDS), who require 1 to 4 packs of Red Blood Cells through transfusion every 8-weeks.EUCTR2017-001773-17-GBFibroGen, Inc.303
进行中（未招募）
1 期
Safety and efficacy study of roxadustat to treat anemia in patients with lower risk Myelodysplastic Syndrome (MDS), who require 1 to 4 packs of Red Blood Cells through transfusion every 8-weeks.EUCTR2017-001773-17-DKFibroGen, Inc.303
进行中（未招募）
1 期
Safety and efficacy study of roxadustat to treat anemia in patients with lower risk Myelodysplastic Syndrome (MDS), who require 1 to 4 packs of Red Blood Cells through transfusion every 8-weeks.EUCTR2017-001773-17-ITFIBROGE303
进行中（未招募）
1 期
Safety and efficacy study of roxadustat to treat anemia in patients with lower risk Myelodysplastic Syndrome (MDS), who require 1 to 4 packs of Red Blood Cells through transfusion every 8-weeks.Anemia due to Myelodysplastic Syndrome (MDS) in International Prognostic Scoring System – Revised Very Low, Low, or Intermediate Risk with <5% Blasts, and has low red blood cell transfusion burden (requires 1 to 4 packed red blood cell units per 8-week period)EUCTR2017-001773-17-DEFibroGen, Inc.184